Our mission is to maximize the benefits of immune therapies for all types of cancer patients
The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $220 million launched by the National Institutes of Health, the FNIH and 12 leading pharmaceutical companies as part of the Cancer MoonshotSM Research Initiatives. PACT is focused on efforts to identify, develop and validate robust biomarkers to advance new therapies and treatments that harness the immune system to attack cancer. The FNIH manages the partnership, with FDA serving in an advisory role.
Not All Patients Respond to Immunotherapies
Immune therapies have been effective in treating certain cancers. Biopharmaceutical companies have focused investments in these therapies, seeking to provide new options for patients who do not respond to other cancer therapies – yet these immune treatments do not work for all patients. Development and standardization of biomarkers to understand how immunotherapies work in some patients, and thus to predict patient responses to treatment, are urgently needed for these therapies to benefit the maximum number of people.
PACT facilitates systematic and uniform clinical testing of biomarkers to advance understanding of the mechanisms of treatment response and resistance to these immunotherapies. The research conducted under the partnership also defines a set of standardized assays to be tested across a variety of studies, aiming to integrate immune and other related oncology biomarkers into clinical trials. This approach supports harmonization of assays and allows for consistent generation of data to enable data reproducibility and comparison of data across trials, and fosters discovery and validation of new biomarkers for immunotherapy and related combinations. PACT also facilitates information sharing by stakeholders across government, academia and industry to better coordinate clinical efforts.
The CIMAC-CIDC Network is a key component of the PACT project. The four Cancer Immune Monitoring and Analysis Centers (CIMACs) – at Dana-Farber Cancer Institute, Stanford University, MD Anderson and Mount Sinai – use analytically validated and standardized platforms to conduct a wide range of cutting-edge analyses for genomic, phenotypic and functional characterization of patient responses during early-phase clinical trials. The Cancer Immunologic Data Commons (CIDC), hosted by Dana-Farber Cancer Institute, provides bioinformatics support, optimizes data collection methodologies suitable for immune-related biomarkers, integrates data for the network and establishes a biomarker database for secondary use by the larger immune oncology research community.Learn More
Private Sector Partners
Public Sector Partners
Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer TherapiesOxford Biodynamics Press Release
It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has DataTrends in Cancer
A Rethink for IO BiomarkersCancer Discovery
The Role of Public-Private Partnerships in the Cancer Moonshot: How PACT can Transform Cancer Immunotherapy Clinical TrialsFNIH Announcement
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)Clinical Cancer Research
Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC networkClinical Cancer Research
Stacey Adam, PhD
Associate Vice President, Science Partnerships[email protected]
Tetyana Murza, MS, MES, PMP
Senior Project Manager, Cancer[email protected]
Project Manager, Cancer[email protected]
Donate to the FNIH today to support medical research that saves lives
Partner With Us
Work with the FNIH to accelerate medical breakthroughs for patients